Abstract
Current biological and pharmacological evidence suggests that the melanocortin 4 and melanocortin 3 receptors which are seven transmembrane G-protein coupled receptors (GPCRs) are involved in various aspects of energy balance and feeding behaviors in animals including humans. The natural endogenous ligands for these receptors are products of the gene pro-opiomelanocortin (POMC), and include α-melanocyte stimulating hormone, γ-melanocyte stimulating hormone and perhaps other modified products of POMC. Thus well designed agonists and antagonists of these ligands might serve as drugs for the treatment of feeding disorders. However, these melanotropin peptides also can have other biological activities that involve the MC3R and MC4R, and these other biological properties will need to be modulated in ligands that are likely to be useful drugs for feeding disorders. Current progress in these areas with special emphasis on the MC3R will be discussed along with possible new directions that might be fruitful in these important aspects of contemporary biology and medicine.
Keywords: Melanocortin genes, melanotropin peptides, MC4R, MC3R, obesity, anorexia
Current Topics in Medicinal Chemistry
Title: Melanotropins as Drugs for the Treatment of Obesity and Other Feeding Disorders: Potential and Problems
Volume: 9 Issue: 6
Author(s): Minying Cai, Joel Nyberg and Victor J. Hruby
Affiliation:
Keywords: Melanocortin genes, melanotropin peptides, MC4R, MC3R, obesity, anorexia
Abstract: Current biological and pharmacological evidence suggests that the melanocortin 4 and melanocortin 3 receptors which are seven transmembrane G-protein coupled receptors (GPCRs) are involved in various aspects of energy balance and feeding behaviors in animals including humans. The natural endogenous ligands for these receptors are products of the gene pro-opiomelanocortin (POMC), and include α-melanocyte stimulating hormone, γ-melanocyte stimulating hormone and perhaps other modified products of POMC. Thus well designed agonists and antagonists of these ligands might serve as drugs for the treatment of feeding disorders. However, these melanotropin peptides also can have other biological activities that involve the MC3R and MC4R, and these other biological properties will need to be modulated in ligands that are likely to be useful drugs for feeding disorders. Current progress in these areas with special emphasis on the MC3R will be discussed along with possible new directions that might be fruitful in these important aspects of contemporary biology and medicine.
Export Options
About this article
Cite this article as:
Cai Minying, Nyberg Joel and Hruby J. Victor, Melanotropins as Drugs for the Treatment of Obesity and Other Feeding Disorders: Potential and Problems, Current Topics in Medicinal Chemistry 2009; 9 (6) . https://dx.doi.org/10.2174/156802609788897817
DOI https://dx.doi.org/10.2174/156802609788897817 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Morphology of Atherosclerotic Plaque: Its Feature by Imaging Study
Current Pharmaceutical Design Biologics in Systemic Sclerosis
Current Pharmaceutical Biotechnology Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem
Current Cardiology Reviews Novel Therapeutic Options in Metastatic Renal Cancer – Review and Post ASCO 2007 Update
Reviews on Recent Clinical Trials Determinants of Perceived Severity of Hypertension and Drug-Compliance in Hypertensive Patients
Cardiovascular & Hematological Disorders-Drug Targets Refining Genetic Approaches for Identifying Behavioral Loci
Current Genomics Oxidative Stress Correlates (OSC) in Diabetes Mellitus Patients
Current Diabetes Reviews Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Diagnostics and Therapy of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitides
Current Pharmaceutical Design Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease
Current Medicinal Chemistry Dual COX Inhibition and Upper Gastrointestinal Damage
Current Pharmaceutical Design Gender Differences in Autonomic Control of the Cardiovascular System
Current Pharmaceutical Design Pharmacological Evidence of α -adrenergic Receptors in the Hypotensive Effect of Chamaemulum nobile L.
Cardiovascular & Hematological Agents in Medicinal Chemistry Ghrelin and Growth Hormone Secretagogues, Physiological and Pharmacological Aspect
Current Drug Discovery Technologies Soluble (Pro) Renin Receptor is a Predictor of Gestational Diabetes Mellitus
Current Diabetes Reviews Recent Development on Anti-Obesity Compounds and their Mechanisms of Action: A Review
Current Medicinal Chemistry Editorial: Obstructive Sleep Apnea (OSA) in the Elderly: Does OSA Decrease Mortality in These Patients When They Have Pneumonia?
Current Respiratory Medicine Reviews Linezolid in Children: Recent Patents and Advances
Recent Patents on Anti-Infective Drug Discovery In Vitro Evaluation of a Hydroxypropyl Cellulose Gel System for Transdermal Delivery of Timolol
Current Drug Delivery Meet Our Associate Editor
Current Molecular Medicine